STAT

As targeted therapies prevail, patient voice and preference should, too

Cancer patients want to beat cancer, full stop. They want medicines to work. But they also want to thrive with fewer side effects and day-to-day disruptions. If efficacy is a top priority in cancer ...
Seeking Alpha

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Seeking Alpha

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Following Priority Review, the U.S. FDA granted HYRNUO ® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) ...
The American Journal of Managed Care

Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL

Ibrutinib's metabolism by CYP3A makes it susceptible to drug interactions, affecting its serum concentration significantly with CYP3A modulators. Despite frequent drug interactions, overall survival ...